Revenue

As Liberty Latin America preps its 2025 results, investors watch to see if strong subscriber growth and cost-cutting can sustain momentum in a competitive market.

Investors and patients await Puma Bio's Q4 results, focusing on NERLYNX sales performance and crucial updates on its promising alisertib cancer pipeline.

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.

The industrial giant posted strong 2025 results and a cautious 2026 outlook, banking on its execution strategy and key acquisitions in high-growth markets.

A jury verdict against Olin Corporation in a contract dispute with Shintech will cost the chemical giant $185 million and raises industry-wide questions.

Forward Industries' radical crypto pivot is a wild ride. Staking revenue is up 4x, but a market downturn triggered a staggering half-billion-dollar loss.

The pet insurance giant swung to a major profit in 2025, but a closer look reveals a complex strategy of focused growth and rising acquisition costs.

Investors eye Globus Medical's upcoming report for a full-year look at its NuVasive integration, market trends, and a pivotal 2025 performance.

Semiconductor giant Victor Peng joins the Rambus board, signaling a strategic move to deepen its dominance in the competitive AI and data center markets.

The SaaS firm posts strong net income and recurring revenue growth from its B2B platform, offsetting a decline in its transactional business.

A new Orlando campus offers vital nursing programs, including a new LPN option, to bolster Central Florida's strained healthcare workforce.

The streaming pioneer smashed Q4 estimates and returned to full-year profitability, signaling a strong 2026 with ambitious growth targets for its ad platform.

Yelp posted record 2025 revenue but forecasts lower 2026 profits as it invests heavily in an AI transformation, including acquiring Hatch and partnering with OpenAI.

Brazil's fintech leader reports a record R$5.2B adjusted net income for 2025, outlining a strategy that pairs AI with human advisors to win the market.

Celcuity adds Seagen commercial veteran Charles Romp to its board, a strategic move signaling its pivot from R&D to market readiness for gedatolisib.

DifGen Pharmaceuticals' new FDA-approved generic eye drop is only the second of its kind, promising to increase competition and lower costs for patients.

Red River's spot on CRN's 2026 Elite 150 list highlights a new era for managed services, driven by complex AI and cybersecurity needs in government and enterprise.

Ground has broken on the John S. McCain III Library and Museum, a landmark project designed to be far more than a memorial, but a hub for future leaders.

A retired Major General leads a $2.5M effort to digitize 360,000 bounty land records, unlocking the hidden histories of early American soldiers.

With results expected to beat guidance, all eyes are on Progyny's upcoming earnings as a key indicator for the rapidly expanding corporate family-building industry.